Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Promptly treating prostate cancer bone metastases with the newest medication ... who use sophisticated imaging technologies such as PET scans, have gotten very good at finding even tiny bone ...

suspected prostate cancer is typically confirmed by taking a biopsy of the prostate and examining it under a microscope. Further tests, such as CT scans and bone scans, may be performed to ...

Signs that the cancer may have spread include bone and back pain ... This can include a prostate-specific antigen (PSA) blood test and a scan, as well as a biopsy, which involves taking a small ...

Radiographic disappearance of metastases could be a surrogate marker for outcomes among patients treated for metastatic hormone-sensitive prostate cancer.

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term ...

A groundbreaking technique developed by scientists at Heriot Watt University in Edinburgh, could offer new hope for faster and more accessible prostate cancer detection. Using existing ultrasound ...

After learning in January that his prostate cancer had become terminal, Doug Ruch returned to his San Antonio apartment and ...

“Our scans are getting better,” says ... People with mCRPC, or any advanced prostate cancer, may experience urinary problems, bone pain, fatigue, and weight loss — or possibly no symptoms ...

A GP surgery in Attleborough has been urged to do more to ensure it learns from patient deaths following the inquest for an 81-year-old ...